 This will be a randomized, double blind, placebo controlled, parallel group study in approximately 90 subjects 60:30 in the active:placebo groups respectively with a pruritus Numerical Rating Scale NRS score of 5 0-10 scale, an Investigators Global Assessment IGA 3 0-5 scale and moderate-severe AD Eczema Area and Severity Index EASI 12 and 48 0-72 scale. Each subject will have a screening visits to confirm suitability to enter the study. At a subsequent visit start of Run In, the subject will be provided with the electronic diary eDiary to capture pruritus, sleep disturbance and emollient use, which must be completed on Days -7 to -1 Run In. Subjects will then attend the clinic at Baseline Day 0 when they will be reviewed to confirm they meet inclusionexclusion criteria and have completed the Run In diary appropriately. If appropriate, they will then be randomized to receive either oral 30 mg ZPL-3893787 once daily od or placebo od for 8 weeks 56 days. 